No profile data available.
Perspective Therapeutics, Inc. (CATX) is a healthcare company in the additional cancer treatment drugs industry, based in Seattle, United States, with about 163 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$103.12 million. Its market capitalization was $303.64 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States.
Perspective Therapeutics reported $0 in revenue for fiscal year 2025.
$303.64 million as of October 9, 2026.
Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Indaptus Therapeutics, Inc. (INDP), Allogene Therapeutics, Inc. (ALLO), Prelude Therapeutics Incorporated (PRLD), CytoDyn Inc. (CYDY).